May 19, 2023 – GEN-001/Avelumab Combination Induces Antitumor Activity in Gastric and GEJ Cancer

Treatment with avelumab (Bavencio) plus GEN-001 in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma has demonstrated positive antitumor activity, according to an announcement by Genome & Company.1

The finding comes from a phase 2 study (NCT05419362) of GEN-001 in combination with avelumab, for which the primary end point is objective response rate (ORR), and the secondary end points are the incidence of adverse events (AEs), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). An exploratory end point in the study is analyzing microbiota.

Read More>